Gene Therapy Medicinal Products GTMP Market Report 2025 (Global Edition)

Global Gene Therapy Medicinal Products GTMP Market Report 2025 Market Size Split by Type (Oral, Injection), by Application (Cancer, Monogenic, Infectious Disease, Cardiovascular Disease, Other)

Gene Therapy Medicinal Products GTMP Market Report Description

We have various report editions of Gene Therapy Medicinal Products GTMP Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Gene Therapy Medicinal Products GTMP Market Insights Video

Competitive Landscape of the Gene Therapy Medicinal Products GTMP Market

The competitive landscape of the gene therapy medicinal products GTMP market is distinguished by a wide variety of participants competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established medical device manufacturers, specialized gene therapy medicinal products, GTMP companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

Top Companies Market Share in Gene Therapy Medicinal Products GTMP Industry: (In no particular order of Rank)

• Bluebird Bio
• Dimension Therapeutics
• Avalanche Bio
• Sangamo
• Spark Therapeutics
• Vical Inc.
• Celladon
• Advantagene
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Gene Therapy Medicinal Products GTMP Market

Which Region Dominates the Gene Therapy Medicinal Products GTMP Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. North America, notably the United States, is home to a large number of top research institutes, universities, and biotechnology corporations. This dynamic R&D environment promotes innovation and advancements in gene therapy technology. The development of innovative gene treatments is driven by significant investment in R&D activities and a strong scientific inquiry culture. The region receives substantial investment from both the governmental and commercial sectors. Venture capital businesses, government grants, and huge pharmaceutical corporations all make significant investments in the biotechnology and gene therapy industries. This financial help speeds up the research and marketing of innovative gene therapy products.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Gene Therapy Medicinal Products GTMP market due to several compelling reasons. ? The biotechnology sector in Asia Pacific is quickly expanding, with nations such as China, Japan, South Korea, and India investing heavily in biotech research and development. This expansion is driving innovation in gene therapy methods and products. Regulatory organizations in Asia-Pacific nations are increasingly supportive of novel cures. For example, China's National Medical Products Administration (NMPA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are introducing speedier approval processes and special designations to accelerate gene therapy development and approval.

 

The current report Scope analyzes Gene Therapy Medicinal Products GTMP Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Gene Therapy Medicinal Products GTMP Market Analysis

According to Cognitive Market Research, the global Gene Therapy Medicinal Products GTMP market size was estimated at USD XX Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Gene Therapy Medicinal Products GTMP market with a market size of USD XX million in 2024 and is projected to grow at a CAGR of 4.0% during the forecast period. The United States healthcare system is typically open to new and innovative therapies. This early adopter mindset allows for faster market penetration of certified GTMPs.
• The Canada Gene Therapy Medicinal Products GTMP market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 5.0% during the forecast period. Canada focuses on research for orphan illnesses, which frequently lack effective medicines. GTMPs show potential in treating these unusual disorders.
• The Mexico Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD XX million in 2024.

Europe Gene Therapy Medicinal Products GTMP Market Analysis

According to Cognitive Market Research, the global Gene Therapy Medicinal Products GTMP market size was estimated at USD XX Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.

• The United Kingdom Gene Therapy Medicinal Products GTMP market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 5.3% during the forecast period. The UK has a thriving cell and gene therapy business, with a large concentration of firms, research institutes, and clinical trials focusing on GTMP research. This critical mass promotes creativity and collaboration.
• The France Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD XX million in 2024.
• According to Cognitive Market Research, the German Gene Therapy Medicinal Products GTMP market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 4.7% during the forecast period. Germany places a great emphasis on scientific and technology education, resulting in a trained workforce in life sciences. This skill pool is critical to GTMP research and development.
• The Italy Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 3.9% during the forecast period, with a market size of USD XX million in 2024.
• The Russia Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 3.5% during the forecast period, with a market size of USD XX million in 2024.
• The Spain Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 3.6% during the forecast period with a market size of USD XX million in 2024
• The Luxembourg Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.6% during the forecast period, with a market size of USD XX million in 2024.
• The Portugal Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.3% during the forecast period, with a market size of USD XX million in 2024.
• The Greece Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD XX million in 2024.
• Rest of Europe's Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 3.2% during the forecast period, with a market size of USD XX million in 2024.

Asia Pacific Gene Therapy Medicinal Products GTMP Market Analysis

According to Cognitive Market Research, the global Gene Therapy Medicinal Products GTMP market size was estimated at USD XX Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Gene Therapy Medicinal Products GTMP market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. China's large population provides a sizable patient pool for GTMPs. This may encourage firms to pursue gene treatments for a broader spectrum of diseases.
• The Japan Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD XX million in 2024.
• The India Gene Therapy Medicinal Products GTMP market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 9.8% during the forecast period. India has a large population with a high frequency of genetic abnormalities and chronic illnesses, which might benefit from GTMPs. This vast patient pool generates a business opportunity.
• The South Korean Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD XX million in 2024.
• The Australia Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD XX million in 2024.
• The South East Asia Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the Asia Pacific Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD XX million in 2024.

South America Gene Therapy Medicinal Products GTMP Market Analysis

According to Cognitive Market Research, the global Gene Therapy Medicinal Products GTMP market size was estimated at USD XX Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Gene Therapy Medicinal Products GTMP market size was valued at USD XX million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. Gene Therapy Medicinal Products GTMP sales flourish in Brazil due to Brazil has high incidence of neglected tropical illnesses like Chagas disease. GTMP research aimed at treating these illnesses might be prioritized, making them more relevant to the Brazilian healthcare system.
• Argentina Gene Therapy Medicinal Products GTMP market had a market share of USD XX million in 2024 and is projected to grow at a CAGR of 6.3% during the forecast period. Due to increased investments in biotech innovation and favorable regulatory frameworks. The country's strong research infrastructure and qualified personnel reinforce its position as a major player in the GTMP industry.
• Colombia Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD XX million in 2024.
• Peru Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 5.6% during the forecast period, with a market size of USD XX million in 2024.
• Chile Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the Latin America Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.5% during the forecast period, with a market size of USD XX million in 2024.

Middle East Gene Therapy Medicinal Products GTMP Market Analysis

According to Cognitive Market Research, the global Gene Therapy Medicinal Products GTMP market size was estimated at USD XX Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD XX million in 2024. It will grow at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

• The GCC Countries Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD XX million in 2024. Some GCC nations, like Saudi Arabia and the UAE, are investing in healthcare and life sciences research. This might result in more financing for GTMP development in the future.
• The Egypt Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD XX million in 2024.
• The South Africa Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD XX million in 2024. Gene treatments offer promise in treating chronic infectious illnesses common in South Africa, such as HIV, which is generating interest and investment in the sector.
• The Turkey Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD XX million in 2024.
• The Nigeria Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD XX million in 2024.
• The Rest of the MEA Gene Therapy Medicinal Products GTMP market is projected to witness growth at a CAGR of 4.7% during the forecast period, with a market size of USD XX million in 2024.

Gene Therapy Medicinal Products GTMP Market Analysis

Gene Therapy Medicinal Products GTMP Market Type Segment Analysis

According to Cognitive Market Research, Oral is the dominating category. Patients often prefer oral delivery to needles or surgery, particularly for chronic illnesses that require long-term care. Increased compliance owing to the simplicity and comfort of taking oral medicine, which is especially significant for juvenile and senior groups. Oral delivery technologies can improve gene therapy for chronic illnesses such as cystic fibrosis, hemophilia, and metabolic disorders. Therapeutic genes may be released continuously and managed, which improves disease management and patient outcomes.

Injection is the fastest-growing category in the Gene Therapy Medicinal Products GTMP market. Injectable gene treatments are utilized to treat a variety of genetic abnormalities, malignancies, and other severe conditions where precise administration is required. Injectable GTMPs have been effective in treating conditions such as spinal muscular atrophy, hemophilia, and certain kinds of congenital blindness. Injections can give a faster beginning of therapeutic activity than oral methods, which is critical in acute and severe conditions. The therapeutic genes' immediate bioavailability guarantees that illnesses can be treated and managed promptly.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Gene Therapy Medicinal Products GTMP Industry. Request a Free Sample PDF!

Gene Therapy Medicinal Products GTMP Market Application Segment Analysis

According to Cognitive Market Research, the dominating category is Cancer. Chimeric Antigen Receptor T-cell (CAR-T) therapy has developed as a ground-breaking gene therapy strategy for treating specific cancers. CAR-T treatments, which change a patient's T-cells to detect better and destroy cancer cells, have demonstrated extraordinary effectiveness, notably in hematological malignancies such as leukemia and lymphoma. This result is driving further research and investment in GTMPs for cancer.

The fastest-growing category in the Gene Therapy Medicinal Products GTMP market is Monogenic. Advances in genomic research and next-generation sequencing have resulted in the discovery of several monogenic diseases. As the list of these ailments grows, so does the possibility of creating gene treatments targeted to these specific genetic defects. Cystic fibrosis, hemophilia, Duchenne muscular dystrophy, and some retinal illnesses are all ideal candidates for gene therapy procedures.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion